ZVSA
ZyVersa Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.00
+0.00%Price chart
Oct 2Oct 7Oct 12Oct 15Oct 20Oct 23Oct 28Nov 3
Key dataNov 3, 2026
Open$0.00
From 52W high−99.63%
Volume77962.00
Market cap$77406.78
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 3, 2026
Open
$0.00
From 52W high
−99.63%
Volume
77962.00
Market cap
$77406.78
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−36.3x
P/E (TTM)
—
RSI (14)
14.8
MomentumView details →
1D Return
+0.00%
YTD Return
−99.25%
SummaryUpdated Mar 1, 2026
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) is a clinical-stage biopharmaceutical company founded and headquartered in Weston, Florida. The company went public in February 2022 and focuses on developing novel therapeutic treatments for renal (kidney) and inflammatory diseases. As a pre-revenue biotechnology company, ZyVersa is currently advancing two primary drug candidates through clinical development: VAR 200 for kidney diseases and IC 100 for inflammatory conditions.
Similar companies
Latest newsMore news →
No recent news for ZVSA.